Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for SAB BIOTHERAPEUTICS, INC. Common Stock, $0.0001 par value per share (SABS).
- Disclosed ownership: 9.9%.
- Date of event: 26 Sep 2025.
Commodore Capital LP - 26 Sep 2025 SCHEDULE 13G Report for SAB BIOTHERAPEUTICS, INC. Common Stock, $0.0001 par value per share (SABS)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- SABS
- Shares outstanding
- 45,686,636 shares
- Disclosed Ownership
- 4,522,977 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 03 Oct 2025, 16:05:22 UTC
- Date of event
- 26 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 9.9% ownership in SAB BIOTHERAPEUTICS, INC. Common Stock, $0.0001 par value per share (SABS) on 26 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Oct 2025, 16:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 4,522,977 | 0 | 4,522,977 | /s/ Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 9.9% | 4,522,977 | 0 | 4,522,977 | /s/ Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 9.9% | 4,522,977 | 0 | 4,522,977 | /s/ Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 9.9% | 4,522,977 | 0 | 4,522,977 | /s/ Michael Kramarz | Authorized Signatory |